
Practice-Changing Medicine
As the COVID-19 pandemic places unprecedented demand on science to deliver solutions, Sanofi scientists are working harder than ever before to develop medicines that improve the lives of people living with disease. By combining a long tradition of leadership in vaccines and small molecules with new strengths in cutting-edge biologics, technologies, and collaborations, our R&D teams are solving seemingly intractable biological problems and delivering practice-changing medicines.
R&D Focus Areas

R&D Portfolio
Sanofi’s R&D pipeline contains 84 projects, including 34 new molecular entities in clinical development or that have been submitted to the regulatory authorities. Thirty-four of these projects are in phase 3 or have been submitted to the regulatory authorities for approval.

Next Generation Technologies
Sanofi is investing in scalable gene therapies, multi-targeting therapies to tackle complex diseases, and combination therapies to make treatments more effective. We are advancing new biologics to produce precision medicines and leveraging AI to accelerate our discovery and development. Our integration of real-world evidence is enabling us to design innovative, decentralized clinical trials, and to identify new patient groups that might benefit from our medicines.
Meet Sanofi's Scientists
The scientists, physicians, technicians, product and manufacturing engineers, and world-class innovators who make up Sanofi's R&D community contribute to its scientific leadership. Together, Sanofi is achieving innovations that can transform, extend, and potentially save lives.
Science & Innovation Stories

Partnering with Us
Collaboration is crucial to success. We are committed to matching our skills and projects with the best professionals and companies, wherever they are in the world.